Compare Merck & Co., Inc. (MRK) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Nano Dimension Ltd - ADR — how do they compare? Merck & Co., Inc. trades at $148.25 (market cap $366.28B), while Nano Dimension Ltd - ADR trades at $1.51 (market cap $327.47M). The key difference: Merck & Co., Inc. is far larger — about 1118.5× Nano Dimension Ltd - ADR's market cap, and Merck & Co., Inc. pays a 2.29% dividend while Nano Dimension Ltd - ADR pays none. Which is the better fit depends on your goals.
| MRK | NNDM | |
|---|---|---|
Market Cap | $366.28B | $327.47M |
Sector | Health | Technology |
52-Week High | $156.43 | $2.14 |
52-Week Low | $77.60 | $1.21 |
Enterprise Value | $413.04B | -$77.38M |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
NNDM trades at $1.555, down 4.01% on the day, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $121M but a net loss of -$163M, reflecting a net margin of -135.18%. Recent strategic moves include appointing a new board member and cost-saving initiatives aimed at reducing cash burn by $25M annually. The balance sheet shows a strong cash position of $757.96M with minimal debt, but operating cash flow remains negative.
The outlook is cautious due to persistent losses and high cash burn, though asset sales and cost cuts may improve liquidity. Investment opportunity lies in the company's cash reserves and potential strategic shifts, but risks include ongoing operational losses and shareholder activism. The stock faces pressure from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
